Diagnostic work-up and risk stratification in patients with bladder cancer before and after treatment must be refined to optimize management and improve outcomes. MRI has been suggested as a non-invasive technique for bladder cancer staging and assessment of response to systemic therapy. The Vesical Imaging-Reporting And Data System (VI-RADS) was developed to standardize bladder MRI image acquisition, interpretation and reporting and enables accurate prediction of muscle-wall invasion of bladder cancer. MRI is available in many centres but is not yet recommended as a first-line test for bladder cancer owing to a lack of high-quality evidence. Consensus-based evidence on the use of MRI-VI-RADS for bladder cancer care is needed to serve as a benchmark for formulating guidelines and research agendas until further evidence from randomized trials becomes available.
Nature reviews. Urology. 2023 Nov 30 [Epub ahead of print]
Valeria Panebianco, Alberto Briganti, Thierry N Boellaard, James Catto, Eva Comperat, Jason Efstathiou, Antoine G van der Heijden, Gianluca Giannarini, Rossano Girometti, Laura Mertens, Mitsuru Takeuchi, Valdair F Muglia, Yoshifumi Narumi, Giacomo Novara, Martina Pecoraro, Morgan Roupret, Francesco Sanguedolce, Daniele Santini, Shahrokh F Shariat, Giuseppe Simone, Hebert A Vargas, Sungmin Woo, Jelle Barentsz, J Alfred Witjes
Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy. ., Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy., Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Academic Urology Unit, University of Sheffield, Sheffield, UK., Department of Pathology, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Hopital Tenon, Paris, France., Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Urology Unit, Academic Medical Centre "Santa Maria della Misericordia", Udine, Italy., Institute of Radiology, Academic Medical Centre "Santa Maria della Misericordia", Udine, Italy., Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., Department of Radiology, Radiolonet Tokai, Nagoya, Japan., Department of Medical Images, Radiation Therapy and Oncohematology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil., Department of Healthcare, Tachibana University, Kyoto, Japan., Department of Surgery, Oncology, and Gastroenterology - Urology Clinic, University of Padua, Padua, Italy., Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy., Department of Urology, Sorbonne University, AP-HP, Pitié Salpétrière Hospital, Paris, France., Department of Urology, Fundació Puigvert, Autonomous University of Barcelona, Barcelona, Spain., Division of Medical Oncology A, Policlinico Umberto I, Rome, Italy., Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic., IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy., Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.